Can a short course of immunotherapy and radiation shrink head and neck tumors before surgery?

NCT ID NCT03247712

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial investigates whether giving the immunotherapy drug nivolumab along with a short course of radiation before surgery can safely shrink tumors and reduce lymph node involvement in people with head and neck squamous cell carcinoma. Participants receive either 3 or 5 days of radiation plus nivolumab, followed by surgical removal of the tumor. The study focuses on safety—specifically whether the pre-surgery treatment causes delays to the planned operation—and also measures how much the tumor shrinks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab (an immunotherapy drug) plus radiation therapy
What this could lead to
If successful, this approach could offer a less toxic way to shrink head and neck cancers before surgery, potentially improving outcomes.
What could go wrong
This is an early-phase trial with only 22 participants, so results may not apply broadly. The combination of immunotherapy and radiation carries risks of immune-related side effects and surgical delays.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.